Dr. Stanley Liauw serves as the Director of Clinical Operations and is the clinical lead for the genitourinary (GU) cancer program and the gastrointestinal (GI) cancer program within the Department of Radiation and Cellular Oncology at the University of Chicago. In the past 10 years on faculty, Dr. Liauw has developed research programs in these disease sites, with an interest in outcomes research and clinical trials. The central mission of his research is to conduct clinical studies to define current clinical outcomes and areas of need, develop hypotheses, and test novel regimens to reduce the morbidity or mortality of radiation therapy in the treatment of cancer.
A major focus of Dr. Liauw's efforts include the periodic analysis and reporting of cancer outcomes with radiation therapy. This work, derived from multiple institutional databases of more than 2000 patients, has resulted in numerous abstract presentations and publications in peer-reviewed journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology, Biology, Physics and Cancer. These contributions generally fall into 3 categories of interest: presenting hypotheses to improve the therapeutic ratio of therapy, studying the use of imaging in radiation oncology, and exploring potential markers of response to therapy.
A number of clinical protocols have been opened for patients with genitourinary and gastrointestinal cancers. Dr. Liauw has investigated and initiated trials for a: phase I study of dose escalated stereotactic body RT trial for unresectable pancreatic cancer, phase II quality of life study of oral hormonal therapy with RT for prostate cancer, phase I study for oligometastatic renal cell cancer, and phase I randomized study for hepatocellular carcinoma treated with RT and immunotherapy.
Outside of his research interests, Dr. Liauw has overseen several intradepartmental projects aimed at improving clinical workflow and patient safety, with potential downstream effects on patient and employee satisfaction. He served as the clinical lead for the implementation of intraoperative radiation therapy in 2015, as an Associate Editor for GI cancers for the International Journal of Radiation Oncology, Biology, and Physics, as an examiner and question writer for the American Board of Radiology for GU cancers, and an invited speaker for national and international educational lectures such as through the American Society of Radiation Oncology (ASTRO) and the American Urological Association. He has been an invited Visiting Professor for resident education at multiple institutions, and has been regularly recognized from the University of Chicago training program as a top educator. He has been an ad hoc reviewer of manuscripts for more than 20 scientific journals, including Journal of Clinical Oncology and the New England Journal of Medicine.
University of Florida
Gainesville, FL
Residency - Radiation Oncology
2006
Brigham and Women's Hospital
Boston, MA
Internship - Internal Medicine
2002
UT Southwestern Medical School
Dallas, TX
MD - Medicine
2001
MIT
Cambridge, MA
BS - Chemical Engineering
1997
Optimizing the Therapeutic Ratio in Prostate Radiation Therapy.
Optimizing the Therapeutic Ratio in Prostate Radiation Therapy. JAMA. 2026 Sep 22; 336(12):1012-1014.
PMID: 42593810
Long-term patient-reported outcomes and toxicity following salvage radiotherapy for biochemical recurrence after radical prostatectomy.
Long-term patient-reported outcomes and toxicity following salvage radiotherapy for biochemical recurrence after radical prostatectomy. Cancer. 2026 Sep 15; 132(18):e70609.
PMID: 42745507
Pelvic MRI Following Total Neoadjuvant Therapy for Rectal Cancer Poorly Predicts a Complete Clinical Response.
Pelvic MRI Following Total Neoadjuvant Therapy for Rectal Cancer Poorly Predicts a Complete Clinical Response. J Surg Oncol. 2026 Jun; 133(8):1016-1022.
PMID: 41987351
FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide.
FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide. Eur Urol. 2026 Feb 10.
PMID: 41672869
Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.
Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial. Clin Cancer Res. 2026 Feb 04; 32(3):479-488.
PMID: 41263694
High-Risk Prostate Cancer Treated with Radiation Therapy: Favorable Outcomes in Men with PSA > 20 as the Sole High-Risk Factor.
High-Risk Prostate Cancer Treated with Radiation Therapy: Favorable Outcomes in Men with PSA > 20 as the Sole High-Risk Factor. J Clin Med. 2026 Jan 30; 15(3).
PMID: 41682800
Resolving Clinically Indeterminate Findings During Anal Cancer Surveillance with TTMV-HPV DNA.
Resolving Clinically Indeterminate Findings During Anal Cancer Surveillance with TTMV-HPV DNA. Cancers (Basel). 2025 Dec 22; 18(1).
PMID: 41514548
Radiation Chronotherapy in Prostate Cancer: Does Time of Day of Radiation Treatment Influence Disease Outcome or Symptom Burden?
Radiation Chronotherapy in Prostate Cancer: Does Time of Day of Radiation Treatment Influence Disease Outcome or Symptom Burden? Cancers (Basel). 2025 Jul 23; 17(15).
PMID: 40805144
Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial.
Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial. JAMA Oncol. 2025 07 01; 11(7):726-734.
PMID: 40372727
The Evolving Management of Radiorecurrent Prostate Cancer.
The Evolving Management of Radiorecurrent Prostate Cancer. Semin Radiat Oncol. 2025 Jul; 35(3):450-462.
PMID: 40516980